Clinical Rounds With Nutrition Support Services by Kovacevich, Debra et al.
73
NCP FORUM
Clinical Rounds With Nutrition Support Services*
From The University of Michigan
Debra S. Kovacevich, RN, MPH, CNSN
Clinical Manager




Correspondence and Reprint Requests: Debra S. Kovacevich,
RN, MPH, Parenteral and Enteral Nutrition Team, University of
Michigan Hospitals, 1500 E Medical Center Drive, UH-B2D301,
Box 0008, Ann Arbor, MI 48109-0008.
*Presented at the A.S.P.E.N. 17th Clinical Congress, February
14-17, 1993, San Diego, CA.
The editors of Nutrition in Clinical Prac-
tice held a session entitled &dquo;NCP Forum:
Clinical Rounds With Nutrition Support
Services&dquo; at the 17th Clinical Congress in
San Dingo, California, last year. Two nutri-
tion support teams presented a case and
described how each member of the team
interacted with the patient to effect a suc-
r ~ce~sful outeame., One team was from the
~~:¡;£a~yela1).~ Clinic ~in-~hiog the other, frorn~
tne University of Michigan in Ann Arbor. .: .
= Below are excerpts from the.Univêt9i’:v’
of Michigan team’s presentation.
1 ?/2 The Parenteral and Enteral Nutrition
.,&dquo; : I£4m . &om ,the University. of Michigan is
made up of a clinical nurse manager three . b
i nurse clinicians, two clinical pharmacists, ° z
and two ,nutrition specialists. Members of
’.,.ik,e’team Presenting this case include --1
<~;’:.~~~~::~:::~:::: . :: jj
~ F ~ ~ s a ~ ~~.~?~~rai ~. ~ouc~.ce ~rae~, .~V~ ~~~ ~~~~~~ ~ ~ H~ ~
s Q , Clinical lYlan.a~e~:&~’ w ~~ ~a _ ~ Pe , y, ~:: . : CI~nical,Man~~,¥:i?:3~:;:H~~:;’:i~¡~~;
~~ ~ ~~ ~ 2 r ~’~t~t~ .~~ ‘ B~ic~r~~i:se~i~,~~~‘, ~.13;s ~~, ~~~1) , ;:. &,..&dquo;., g,’ - CNSD’
4~ ~° ~ ;° &euro;)linical utx*iti<M ’ ~;::; 








~~ , 0 . j , _ t: #]joical .:.. ’l &dquo; Pharmacist . ~ ; ..
~~~~avid.’august, MD, cU~i~a1’ dire~tor o~
’&dquo;’°b6ih’th£’Chr£ Teahi.apgihe ~teer~i:r~~e~c~~-
~. or. :n:titiee managed the case but was unable to
r~Ø11ticipate.
>... &dquo; ~.--- .. ------ ----. -.
Ms Kovacevich: The patient, HH, is 19 years old;
his height is 206 cm (6 ft 9 in.); and his weight is 91.8
kg (around 202 lb). He had no previous medical or
nutritional history. He came to our emergency facility
with a 60-hour history of severe abdominal pain.
Findings on physical examination were as follows:
heart rate, 150 bpm; respiratory rate, 42 bpm; tem-
perature, 37.9°C; orthostatic hypotension. Laboratory
findings were significant for a white blood cell count of
11.3 x IOI/L, with 54% bands. Other findings were a
serum HC03 of 16 mEq/L; elevated liver enzyme tests,
specifically SGOT and SGPT over 2000 IU; and a
prothrombin time of 19.3 seconds.
HH was immediately taken to the operating room
following rapid fluid resuscitation. An exploratory
laparotomy showed necrotic bowel extending from the
midjejunum to the splenic flexure of the colon. The
liver was ischemic. Neither the celiac axis nor superior
mesenteric artery pulses were present. However,
pulses were detected in the aorta and both renal
arteries.
The necrotic bowel was resected, leaving an end-
jejunostomy and a Hartmann’s pouch up to the
midascending colon; about 200 cm of viable small
bowel remained. He was immediately taken to the
radiology department for further evaluation of the
splanchnic ischemia. Angiography (Fig. 1) showed
flow to his renal arteries but no flow to the celiac or the
superior mesenteric artery. He was again taken im-
mediately to the operating room, where his liver was
revascularized by means of an autogenous reverse
saphenous vein graft from the right common iliac
artery to the proper hepatic artery. Collateral circula-
tion via the gastroduodenal artery also helped restore
blood flow to the remaining small bowel.
Forty-eight hours later HH was taken to the oper-
ating room for a second-look laparotomy. His bowel
and liver were well perfused, and a gastrostomy tube
was placed to facilitate drainage and to begin early
enteral feedings.
Postoperatively, the patient had persistent elevated
liver function tests and sepsis. On July 3 a heart
murmur was detected. A cardiac ultrasound revealed
an aortic dissection and a probable marfanoid aorta,
which was later confirmed by angiogram. Figure 2
shows the results of the second angiogram, which
indicated that the aorta was more than twice the
normal size.
The physical examination and laboratory findings
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suggested a possible diagnosis of Marfan syndrome. Let
me briefly review the signs and symptoms of this disorder.
Marfan’s syndrome is an autosomal dominant, in-
herited disorder of collagen that affects four to six
people per 100,000. Clinical signs include subluxation
of the lens of the eye, arachnodactyly, extreme limb
length, aortic dissection, and aortic valve incompe-
tence. HH displayed all these signs.
Life expectancy of an individual with Marfan’s
syndrome is about 30 to 40 years. Approximately 95%
of all deaths are related to cardiovascular complica-
tions, specifically aortic rupture. The condition is
diagnosed anthropometrically by measuring the arm
span and comparing it with the patient’s height. HH’s
arm span was a foot longer than his height. Normally
the two measurements are about the same.
Such patients usually are taken immediately to the
operating room to correct the dissection. However, HH
still had considerable hemostatic instability and re-
mained septic. He had a large wound to granulate;
therefore, surgery was delayed until these conditions
were resolved.
Figure 1. Abdominal aortogram obtained immediately
following initial laparotomy for resection of necrotic bowel.
Renal arteries are apparently normal, but the celiac and
superior mesenteric arteries are not seen. There is no
intimal flap visible in this study. After the angiogram, the
patient was immediately returned to the operating room
for revascularization of his splanchnic circulation.
Dr August decided on conservative therapy, which
consisted of aggressive enteral and parenteral nutri-
tion support (basically parenteral, because enteral
support failed) and antibiotic therapy. However, re-
fractory hypertension developed, which was thought
secondary to further extension of the dissection to the
renal arteries. Fenestration of the dissection in the
abdominal aorta was performed angiographicallywith
a guidewire and dilating balloon (Fig. 3). The patient’s
hypertension improved dramatically. About 10 days
after complete resolution of all his signs and symptoms
of sepsis, his aortic valve, aortic root, and ascending
thoracic aorta were replaced with a composite graft.
POSTOPERATIVE RECOVERY
HH recovered slowly but uneventfully from this
procedure. However, during his 2 months of hospital-
ization, he became very dependent on his mother. He
wouldn’t let her out of his sight, and she became the
primary decision-maker for him. This was surprising,
because he seemed to be a fairly independent person.
Figure 2. Thoracic aortogram obtained 5 days after admis-
sion. The aortic root is dilated and an intimal flap is barely
visible in the descending thoracic aorta approximately 5 cm
distal to the aortic arch.
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He had graduated from high school and moved to
Florida, where he completed one successful year of
college. To help him regain his independence, the
medical team wanted to send him home as soon as
possible. We tried several times to feed him enterally
but failed.
Ultimately, the patient was discharged on home
parenteral nutrition (HPN) August 31. Two weeks
later after his discharge, he was readmitted for cath-
Figure 3. Fenestration of the intimal flap within the
abdominal aorta to improve renal blood flow and palliate
renovascular hypertension. The catheter was inserted
percutaneously via the right femoral artery. The catheter
was then manipulated so that the balloon traversed the
intimal flap, passing from the true lumen caudal to the false
lumen cephalad. Inflation of the balloon created a common
lumen, augmenting renal blood flow and simplifying man-
agement of the patient’s hypertension.
eter sepsis. At that time the medical team evaluated
the risks and the long-term plan for HH. Dr August
was to take down his jejunostomy in 6 months to 1
year. However, we wondered if the risk of malnutri-
tion was greater than the risk of infection of the valve
and the graft from placing another catheter.
Dr August elected to use the gastrostomy tube and
discharged HH home on tube feedings. He was subse-
quently readmitted twice for dehydration; his jejunos-
tomy was finally taken down in October and his
gastrointestinal tract continuity restored. Ms
Braunschweig will discuss nutrition support for the
patient.
NUTRITIONAL GOALS
Ms Braunschweig: Our first goal of nutrition
support is to maintain the patient’s admission nutri-
tional status. That is almost never possible for some-
one as critically ill-though well nourished-as HH
was. Our goal for patients admitted to the intensive
care unit is not to replenish but rather to maintain the
admission nutritional status. We try to introduce
enteral nutrition support as soon as possible.
In HH’s case, the second component of management
consisted of electrolyte manipulation. As mentioned
earlier, HH had problems with hypertension before
fenestration was performed, and we had to manipu-
late the electrolytes accordingly. Despite renal insuf-
ficiency, he never required dialysis; we manipulated
the TPN solution to meet the requirements. He also
had hypersecretion of gastric acid (routinely associ-
ated with extensive small-bowel resection); we man-
aged that problem with H2 antagonists.
CALORIC NEEDS
We rely heavily on our institution’s metabolic labo-
ratory, which uses indirect calorimetry to determine a
patient’s caloric needs. This was particularly useful
with HH, who was young, very ill, and unusually
large. Without indirect calorimetry I would have
estimated his caloric requirements to be much higher
than what they actually were.
HH’s resting energy expenditure needs ranged
from 2500 to 3300 kcal, and we estimated his protein
needs at 1.2 to 1.5 g/kg of ideal body weight. We began
his nutrition support with our standard amino acid/
dextrose solution and increased the percent amino
acids to 6% with 25% dextrose and one 500-mL bottle
of a 20% lipid to provide appoximately 3000 kcal and
120 g of protein per day.
The electrolyte composition was distinct from our
standard formulation in that we increased the sodium
chloride content to about half normal saline. We
maximized the amount of potassium at 80 mEq/L. We
also maximized the amount of magnesium because he
was being so heavily diuresed. He received the stan-
dard trace element multivitamin package and ranitidine
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at 200 mg per day. This is higher than the standard
dose of 150 mg per day, but because of his size the
change was deemed necessary.
MICRONUTRIENT NEEDS
It is not easy to know the micronutrient needs for a
physiologically unique individual such as HH (Fig. 4).
HH stands about a foot taller than the average man,
forwhom the recommended dietary allowances (RDAs)
were established, and his daily requirements are
excessive-more than 3000 kcal. The RDAs were estab-
lished essentially to meet 98% of the needs of healthy
individuals, which is effectively what trace elements
in standard vitamin supplementations are intended
for. HH would represent an alpha error; he does not fit
on the bell-shaped curve.
As mentioned, HH was well nourished and had no
medical history when he came to us. But when I start
infusing more than 3000 calories in a patient, I wonder
whether the vitamins will meet the patient’s require-
ments, because the needs for some nutrients are
determined by the amount of calories received. Usu-
ally, if a patient initially receives two feedings, this is
not a problem. With increased feeding, the patient
receives more micronutrients, vitamins, and miner-
als. But for patients on TPN it is a one-size-fits-all
solution, and one wonders whether it will be adequate.
The nutrients that predominantly concern us are
thiamin, riboflavin, niacin, and pyridoxine. HH needed
three times the normal amounts of these nutrients
which were adequately provided with the standard
MVI dose. We occasionallv double the MVI dose for 5
Figure 4. HH at age 21 (with his mother).
to 10 days with depleted patients who have high
caloric requirements. We use these trace element and
vitamin packages to meet individual requirements,
and with HH, we clearly needed to address this.
ENTERAL SUPPORT
We had to consider two areas regarding introducing
enteral support: gastric versus small-bowel route, and
polymeric versus defined elemental formula. The lit-
erature supports proceeding as proximally as possible
with patients who have had a significant small-bowel
resection. The goal is to expose the remaining intes-
tine to the nutrition so as to get maximum hypertro-
phy of the gastrointestinal remnant. The same applies
to the polymeric versus the elemental formula. The
literature supports polymeric because exposure to
more complex nutrients results in maximal hypertro-
phy of the remnant.
It has previously been determined that for success-
ful nutrition support of patients who have had exten-
sive small-bowel resection, the chance of effective
enteral support is much more favorable under the
following conditions: the extent of the resection is less
than 80%, the jejunum rather than the ileum has been
resected, no gastrointestinal disease is present in the
remaining bowel, and the patient still has an ileocecal
valve.
Less than 80% of HH’s bowel was resected, but he
had no ileum. There was no disease in the gastrointes-
tinal remnants, but he had no ileocecal valve, and a
large percentage of his colon was resected. In patients
with no ileum, a primary concern is that bile acid will
be depleted toward the end of each day. Such patients
cannot resorb the bile acids without the terminal
ileum,where this kind of absorption takes place. They
also become deficient in vitamin B 12 and for the rest of
their lives must depend on B12 injections.
Another concern regarding HH was malabsorption
as a result of bile acid loss. Only the proximal portion
of the small bowel remained, and transit time through
that portion of the bowel is much more rapid than it is
through the more distal portion. Therefore, we tried to
manipulate the enteral support for HH. It took several
months for his gastrointestinal tract to become hyper-
trophic enough for successful oral feeding with some
enteral feedings at night.
PATIENT COMPLIANCE
Another problem was his noncompliance with low-
fat diet restriction. As mentioned earlier, HH re-
gressed to about age 15 during his hospital stay. When
I tried to talk to him about limiting his fat intake (he
ate large quantities of high-fat foods), he said that his
idea of a major compromise was to go from whole milk
to 2%, nothing more. He refused any further dietary
modifications.
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After HH’s aortic valve, aortic root, and ascending
aorta were repaired, he required permanent anti-
coagulation. As a result of drug-nutrient interactions,
some alterations in nutrition support were necessary.
The need for anticoagulation created a unique situa-
tion, because our protocol is to add 5 mg of vitamin K
to all PN solutions for adult patients once per week.
However, the primary care service HH was using at
the time initiated warfarin therapy and elected to
delete the 5-mg dose of vitamin K from his PN. This
regimen gradually led to vitamin K deficiency and
excessive anticoagulation (prothrombin time greater
than 24 seconds without warfarin). The patient’s PN
solution was ultimately supplemented with 1 mg of
vitamin K per day, which permitted safe and predict-
able anticoagulation with concurrent warfarin therapy.
VITAMIN K METABOLISM
Dr Couch: The need to anticoagulate HH created
for us a unique situation. Our protocol dictates the
addition of 5 mg of vitamin K to each TPN solution for
adults once weekly. The primary care service initially
elected to delete all vitamin K from the TPN solution
when HH began warfarin therapy. Before I discuss
what I recommended, I want to briefly review vitamin
K metabolism.
Metabolically, vitamin K is oxidized via a vitamin
K-dependent carboxylase enzyme. This reaction re-
sults in the formation of 2,3-vitamin K epoxide, an
inactive metabolite. This reaction, which occurs in the
presence of co2 and molecular oxygen, is important in
that during oxidation, glutamic acid residues on the
precursor proteins for inactive clotting factors un-
dergo gamma-carboxylation to form gamma-
carboxyglutamate residues. Gamma-carboxylation of
the clotting factors render them active, enabling them
to chelate calcium ions on phospholipid membranes.
This interaction facilitates clot formation following
injury. In the course of its metabolism, 2,3-vitamin K
is subsequently reduced, ultimately resulting in the
formation of the active naphthohydroquinone cofac-
tor. This process is highly effective in recycling vita-
min K epoxide so that it can once again be oxidized and
therefore activate clotting factors.
In HH, or any patient receiving anticoagulant
therapy, this cycle is interrupted. Specifically, warfa-
rin blocks the action of the reductase enzymes, prohib-
iting regeneration of the active form of vitamin K. If
vitamin K is not regenerated endogenously and is also
deleted from a TPN solution, a vitamin K deficiency
may result in conjunction with the existence of
nonfunctional clotting factors. A vitamin K deficiency,
coupled with warfarin therapy, may predispose a
patient to excessive anticoagulation and increase the
risk of hemorrhage.
In addition, vitamin K is an important cofactor in
the gamma-carboxylation of other proteins, such as
osteocalcin, which is involved in bone formation.
Finally, proteins C and S, which are involved in
inactivation of clotting factors V and VIII, also require
gamma-carboxylation for activation.
We did not want HH to become vitamin-K deficient,
but our current protocol of administering 5 mg of
vitamin K once per week was not ideal, either, because
we could overcorrect his coagulation status or block
the action warfarin for an extended period. At this
point we needed to develop an alternative method of
administering vitamin K to HH.
In 1975 Anderson and Godal administered 1 mg of
intravenous vitamin K to 20 patients who were receiv-
ing warfarin therapy. Before receiving vitamin K, all
20 patients had thrombotests within the therapeutic
range of 5% and 10% of normal, indicative of a steady
state ofhypocoagulability. Administration of the 1 mg
of vitamin K resulted in a moderate reduction of
warfarin’s anticoagulant effect, evidenced by a
thrombotest >12%. The investigators believed, there-
fore, that they were able to maintain a predictable
state of anticoagulation and prevent excessive bleed-
ing by using 1 mg of vitamin K.
In 1992 Shetty and colleagues studied 31 patients
receiving warfarin therapy who were in a steady state
of anticoagulation. They divided the patients into two
groups; one group (21 patients) received 0.5 mg of
intravenous vitamin K, and the second group (10
patients) received 1 mg. International normalized
ratios (INRs) were between 2 and 5.5 in the group of
patients receiving 0.5 mg of vitamin K 24 hours after
the dose was given. This is consistent with a stable
state of anticoagulation. According to the guidelines
established by the British Society of Haematology,
INRs between 4.5 to 7 reflect excessive anticoagulation.
Thus these investigators believed that the 0.5-mg dose
was enough to maintain predictable anticoagulation.
It is interesting that 5 of the 10 patients in the group
receiving the 1-mg dose had INRs less than 2, which
is thought to correlate with inadequate anticoagulation.
Thus these investigators concluded that 0.5 mg of
vitamin Kwas sufficient for maintaining a predictable
state of anticoagulation in patients receiving concur-
rent warfarin therapy.
Because of HH’s unusually large size, we elected to
maintain him on 1 mg of vitamin K daily while he
received TPN and a daily dose of warfarin. With this
regimen we were able to maintain a predictable state
of anticoagulation, evidenced by the patient’s pro-
thrombin times, which averaged between 15 and 18
seconds.
When HH was discharged from the hospital, he was
no longer receiving TPN therapy and was able to
obtain the necessary amount of vitamin K from his
diet. He has done well since, continuing with 5 mg of
warfarin per day and maintaining a predictable state
of anticoagulation.
OUTCOME
Currently, HH is doing well. He is maintaining
adequate nutritional status with a low-fat oral diet
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and 500 mL of a moderate protein, isotonic tube
feeding on a nightly basis. He is also working full time.
AUDIENCE QUESTIONS
Question: You indicate that there were several
attempts to feed the patient. What products were used
in these attempts? How long was the gut inactive
before enteral feeding was attempted? On what basis
did you decide that enteral feeding was not possible?
Ms Braunschweig: The products used were ini-
tially Osmolite HN-not tolerated at 20 mL/hr, switched
to 1/2 strength Criticare-not tolerated at 20 mL/hr.
Attempts at enteral feeding were tried on the fifth
postoperative day. Feedings were stopped because of
distention and high residuals (> twice the previous
hourly volume).
Question: If enteral nutrition cannot be used to
deliver all the nutrients required, was any consider-
ation given to providing some of the feeding enterally?
Ms Braunschweig: Initially enteral feedings were
not used because everything infused came out rapidly
and with little digestion. With time, the gut did adapt
and enteral support was provided in the evenings.
TPN was weaned and the patient was maintained on
an oral diet with cyclic night enteral feedings.
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